Role of the renin-angiotensin system in cardiac hypertrophy

T Yamazaki1, I Komuro, Y Yazaki

  • 1Department of Cardiovascular Medicine, Graduate School of Medicine, University of Tokyo, Japan.

Insights

Mechanical stretch, a key factor in cardiac hypertrophy due to hypertension, activates pathways independent of angiotensin II. Understanding these mechanisms is crucial for developing effective hypertension treatments and preventing heart disease.

Area of Science:

  • Cardiovascular Physiology
  • Molecular Cardiology
  • Pharmacology

Background:

  • Cardiac hypertrophy, an adaptive heart response to hemodynamic overload like hypertension, is a major risk factor for heart disease.
  • Mechanical stretch from hypertension initiates cardiac hypertrophy, necessitating research into its mechanisms and pharmaceutical interventions.

Purpose of the Study:

  • To investigate the role of mechanical stretch in cardiac hypertrophy.
  • To elucidate the signaling pathways involved in mechanical stretch-induced cardiac hypertrophy, particularly the involvement of angiotensin II.

Main Methods:

  • In vivo studies using spontaneously hypertensive rats treated with TCV116 (angiotensin II type 1 receptor antagonist) or hydralazine.
  • In vitro studies using cultured neonatal rat cardiomyocytes subjected to mechanical stretch.
  • Analysis of extracellular signal-regulated kinase (ERK) activation in angiotensin II type 1a receptor knockout mice and wild-type mice under mechanical stretch.

Main Results:

  • TCV116 reduced cardiac hypertrophy markers in rats, while hydralazine did not.
  • Mechanical stretch activated ERK and increased protein synthesis in cardiomyocytes, with elevated angiotensin II and endothelin-1 levels.
  • Mechanical stretch induced ERK activation in cardiomyocytes from knockout mice, suggesting angiotensin II is not indispensable for this response.
  • Distinct signaling pathways for ERK activation were observed in cardiac fibroblasts and cardiomyocytes.

Conclusions:

  • Mechanical stretch can induce cardiac hypertrophy independently of angiotensin II.
  • Understanding the differential signaling pathways of mechanical stretch-induced cardiac hypertrophy is vital for targeted pharmaceutical interventions.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
Hormonal Regulation01:33

Hormonal Regulation

The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...